As the Ebola outbreak in the Democratic Republic of the Congo (DRC) grew by six cases today, early data show that mAB114, a monoclonal antibody treatment for the disease, is safe and well-tolerated in adults, according to the results from the first human trial of the drug published today in The Lancet.

Derived from the blood of a person who survived an Ebola infection in 1995, mAB114 is an antibody that in earlier studies provided full protection against Ebola in animals, including non-human primates.

Credit: Athalia Christie

Read more at CIDRAP…

See also

Jan 25 Lancet study

Jan 25 Lancet commentary

Jan 25 NIH press release

Jan 25 DRC update

Jan 24 WHO update